Degron Therapeutics raises $40 million in series A round led by LAPAM CAPITAL

Other investors in the round include GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital. With this latest funding, Degron’s total capital raised has reached US$95 million.

The funding will help advance Degron’s main drug program, DEG6498, which is a first-in-class HuR molecular glue degrader. The treatment entered clinical trials in late 2025, and the first patient received the drug in November.

DEG6498 is designed to target HuR, a protein linked to cancer, inflammation, and metabolic diseases that was previously considered difficult to treat with drugs. The drug is currently being tested in a Phase 1 clinical trial involving patients with advanced solid tumors.

"We are thrilled to welcome this distinguished group of investors who share our vision for transforming the treatment of serious diseases with high unmet need through our innovative MGD platform," said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. "This financing will support the continued advancement of our clinical-stage and preclinical pipeline and further strengthen our technology platform. The strong interest from leading healthcare investors underscores confidence in our approach to developing novel MGDs. With our first-in-class HuR program now advancing in the clinic and two additional immunology programs approaching pre-clinical development, we are making significant progress toward our goal of delivering breakthrough therapies to improve patients' lives."

“We are pleased to lead this financing round for Degron. Targeted protein degradation remains a key focus for us, and Degron’s proprietary molecular glue platform, built on deep expertise and a strong data foundation, demonstrates robust capabilities in discovering novel targets and compounds, including for historically undruggable targets,” said Mr. Zhihua Yu, Chairman of Lapam Capital, which led the financing. “We are impressed by the team’s strengths across R&D, translational development, and business development. With this financing, we believe Degron is well-positioned to advance its pipeline efficiently and generate compelling clinical data to benefit patients.”

Founded in 2021 by Yong Cang, Degron Therapeutics has developed its own molecular glue degrader discovery platform called GlueXplorer®. Using this platform, the company has created more than 10,000 different MGD compounds based on over 150 new non-IMiDs molecular structures.

The platform helps Degron discover treatments for disease-causing proteins that were previously considered very difficult to target with traditional small-molecule drugs. This has allowed the company to build a growing pipeline of potential therapies for multiple diseases.

Read More- TruKKer Raises Up to $300 Million Financing Facility from ADCB